Understanding Pharmacokinetic Variability of Pomalidomide: A Physiologically Based Pharmacokinetic Analysis of Disease-Related Physiology, Ethnicity, Hepatic Impairment, Food Effects, Drug Interactions, and Smoking.

Jeffry Adiwidjaja^1,2, Alan V Boddy³, Andrew J McLachlan⁴

¹Sydney Pharmacy School, The University of Sydney, Science Road, Camperdown Campus, Sydney, NSW, 2006, Australia. jeffry.adiwidjaja@sydney.edu.au.

²Simulations Plus, Inc., Research Triangle Park, NC, USA. jeffry.adiwidjaja@sydney.edu.au.

³School of Pharmacy and Biomedical Sciences, Adelaide University, Adelaide, SA, Australia.

⁴Sydney Pharmacy School, The University of Sydney, Science Road, Camperdown Campus, Sydney, NSW, 2006, Australia.

PubMed DOI

Abstract

BACKGROUND AND OBJECTIVE: Understanding interindividual pharmacokinetic variability and potential for drug interactions is of clinical importance for pomalidomide given its long-term use in patients with relapsed and/or refractory multiple myeloma (RRMM). This study aimed to develop a physiologically based pharmacokinetic (PBPK) model of pomalidomide that integrates multiple sources of pharmacokin…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.